ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,334,569 | -23.7% | 1,228,245 | -13.6% | 0.23% | -30.5% |
| Q2 2023 | $43,683,692 | +89.9% | 1,421,070 | +122.6% | 0.32% | +61.7% |
| Q1 2023 | $23,001,336 | +13.4% | 638,394 | +24.4% | 0.20% | -4.3% |
| Q4 2022 | $20,274,827 | +36.0% | 513,027 | +44.6% | 0.21% | +22.8% |
| Q2 2022 | $14,913,000 | +421.6% | 354,729 | +383.3% | 0.17% | +434.4% |
| Q1 2022 | $2,859,000 | -36.7% | 73,394 | -41.3% | 0.03% | -42.9% |
| Q3 2021 | $4,518,000 | -68.7% | 125,000 | -64.4% | 0.06% | -66.5% |
| Q2 2021 | $14,412,000 | +1.2% | 351,597 | +7.7% | 0.17% | -9.2% |
| Q1 2021 | $14,246,000 | -62.7% | 326,597 | -57.2% | 0.18% | -65.9% |
| Q4 2020 | $38,229,000 | +80.4% | 763,817 | +51.6% | 0.54% | +67.7% |
| Q3 2020 | $21,192,000 | +0.3% | 503,735 | +15.7% | 0.32% | +0.6% |
| Q2 2020 | $21,129,000 | – | 435,195 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |